Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits

Diabetes Care. 2010 Feb;33(2):428-33. doi: 10.2337/dc09-1499.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / epidemiology
  • Drug Administration Schedule
  • Exenatide
  • Glucagon-Like Peptide 1 / agonists
  • Humans
  • Hypoglycemic Agents / classification
  • Hypoglycemic Agents / therapeutic use*
  • Incidence
  • Incretins / adverse effects
  • Incretins / therapeutic use*
  • Peptides / administration & dosage
  • Peptides / therapeutic use
  • Prevalence
  • Risk Assessment
  • Treatment Outcome
  • Venoms / administration & dosage
  • Venoms / therapeutic use

Substances

  • Hypoglycemic Agents
  • Incretins
  • Peptides
  • Venoms
  • Glucagon-Like Peptide 1
  • Exenatide